Company Overview
American Healthcare Capital is pleased to exclusively represent the Sale of a U.S. patent for a Smoking Cessation therapy product. People who smoke, as well as those who are exposed to second-hand smoke, develop a range of potentially fatal diseases such as a variety of cancers, coronary and cardiovascular diseases leading to heart attacks and stroke, chronic obstructive pulmonary disease (COPD), and immune suppression. These are all due to depleted micronutrients and antioxidants in the body.
By replenishing depleted micronutrients and antioxidants with the patented formulation, the morbidity and mortality rates are significantly decreased, there are improvements in numerous biomarkers, and people are given a fighting chance to stay well and live longer.
Financial Overview
The global cessation products market was estimated at $24 Billion in 2022 and is expected to reach $57 Billion by 2023, showing a CAGR rate of 9.2%.
The holder of this Patent for a smoking cessation therapy product is a well-recognized wellness physician. He is seeking a strategic partner and a financial sponsor to help manufacture his patented formulation in various forms, such as tablets, capsules, drops, and lozenges, to help market this product initially in the U.S., and to finally make it available for global distribution. He is open to all deal structures, including the sale of his U.S. Patent and earning perpetual royalties.
Asking Price
The Asking Price is to be determined.
